EP0563323A4 - Hiv reverse transcriptase vaccine - Google Patents

Hiv reverse transcriptase vaccine

Info

Publication number
EP0563323A4
EP0563323A4 EP92904337A EP92904337A EP0563323A4 EP 0563323 A4 EP0563323 A4 EP 0563323A4 EP 92904337 A EP92904337 A EP 92904337A EP 92904337 A EP92904337 A EP 92904337A EP 0563323 A4 EP0563323 A4 EP 0563323A4
Authority
EP
European Patent Office
Prior art keywords
vaccine
reverse transcriptase
hiv reverse
hiv
transcriptase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92904337A
Other versions
EP0563323A1 (en
Inventor
Adolph J Ferro
Richard K Bestwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orasure Technologies Inc
Original Assignee
Epitope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitope Inc filed Critical Epitope Inc
Publication of EP0563323A1 publication Critical patent/EP0563323A1/en
Publication of EP0563323A4 publication Critical patent/EP0563323A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP92904337A 1990-12-19 1991-12-18 Hiv reverse transcriptase vaccine Withdrawn EP0563323A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63025590A 1990-12-19 1990-12-19
US630255 1990-12-19

Publications (2)

Publication Number Publication Date
EP0563323A1 EP0563323A1 (en) 1993-10-06
EP0563323A4 true EP0563323A4 (en) 1996-02-28

Family

ID=24526429

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92904337A Withdrawn EP0563323A4 (en) 1990-12-19 1991-12-18 Hiv reverse transcriptase vaccine

Country Status (3)

Country Link
EP (1) EP0563323A4 (en)
AU (1) AU9179891A (en)
WO (1) WO1992011028A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156102A1 (en) * 1991-06-14 2001-11-21 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
DK0586076T3 (en) * 1992-08-07 2003-10-20 Wyeth Corp Recombinant adenovirus vaccines
FR2700957B1 (en) * 1993-01-29 1995-03-03 Seppic Sa Composition of a live recombinant subunit vaccine and method of preparation.
DK0638316T3 (en) * 1993-08-11 2003-09-22 Wyeth Corp Recombinant adenovirus vaccines
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
IL137680A0 (en) * 1998-02-06 2001-10-31 Res Dev Foundation Live vaccine for human immunodeficiency virus
US8367315B2 (en) 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007296A1 (en) * 1986-05-20 1987-12-03 The Trustees Of Columbia University In The City Of Expression of human t-cell lymphotropic virus (htlv-iii) reverse transcriptase and uses thereof
EP0372904A2 (en) * 1988-12-07 1990-06-13 The Research Foundation for Microbial Diseases of Osaka University Protease, reverse transcriptase, and endonuclease of retroviruses and method for producing these enzymes
WO1990010230A1 (en) * 1989-02-23 1990-09-07 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
WO1991013910A1 (en) * 1990-03-09 1991-09-19 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Peptides stimulating cytotoxic t cells immune to hiv rt

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007296A1 (en) * 1986-05-20 1987-12-03 The Trustees Of Columbia University In The City Of Expression of human t-cell lymphotropic virus (htlv-iii) reverse transcriptase and uses thereof
EP0372904A2 (en) * 1988-12-07 1990-06-13 The Research Foundation for Microbial Diseases of Osaka University Protease, reverse transcriptase, and endonuclease of retroviruses and method for producing these enzymes
WO1990010230A1 (en) * 1989-02-23 1990-09-07 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
WO1991013910A1 (en) * 1990-03-09 1991-09-19 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Peptides stimulating cytotoxic t cells immune to hiv rt

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FLEXNER, C. ET AL.: "Characterization of human Immunodeficiency Virus gag-pol gene products expressed by recombinant vaccinia viruses", VIROLOGY, vol. 166, no. 2, pages 339 - 349 *
LI, X. ET AL.: "Generation and characterization of murine monoclonal antibodies reactive against N-terminaland other regions of HIV-1 Reverse Transcriptase", JOURNAL OF MEDICAL VIROLOGY, vol. 39, no. 3, pages 251 - 259 *
LOWE, D.M. ET AL.: "HIV-1 Reverse Transcriptase: crystallization and analysis domain structure by limited proteolysis", BIOCHEMISTRY, vol. 27, no. 25, 13 December 1988 (1988-12-13), EASTON, PA US, pages 8884 - 8889 *
MÜLLER, B. ET AL.: "Co-expression of the subunits of the heterodimer of HIV-1 Reverse Transcriptase in Escherichia coli", JOURNAL OF BIOLOGICAL CHEMISTRY (MICROFILMS), vol. 264, no. 24, 25 August 1989 (1989-08-25), MD US, pages 13975 - 13978 *
See also references of WO9211028A1 *

Also Published As

Publication number Publication date
WO1992011028A1 (en) 1992-07-09
AU9179891A (en) 1992-07-22
EP0563323A1 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
EP0462800A3 (en) Inhibitors of hiv reverse transcriptase
GB9001766D0 (en) Vaccines
GB2189995B (en) Pharmaceutical forms having special release properties.
DK184788A (en) CYTOTOXIC PREPARATION
GB8907914D0 (en) Vaccine preparation
ZA911908B (en) Micro-emulsions
EP0391997A4 (en) Vaccine
ZA924150B (en) Vaccine for human immunodeficiency virus
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
NO922728D0 (en) Vaccine against COCCIDIOSIS
EP0563323A4 (en) Hiv reverse transcriptase vaccine
ZA879023B (en) Conjugate vaccine
ZW22487A1 (en) Vaccine
GB9017370D0 (en) Tuberculosis vaccine
OA09308A (en) Anti-HIV agent.
EP0266401A4 (en) Vaccine.
EP0462808A3 (en) Inhibitors of hiv reverse transcriptase
IL79740A0 (en) Hepatitis vaccine
ZA896372B (en) Vaccine
EP0438711A3 (en) Polysilazanes, their preparation and use
GB8627305D0 (en) Autogenous vaccine
ZA914653B (en) Inhibitors of hiv reverse transcriptase
GB9020584D0 (en) Vaccine
EP0453452A4 (en) Vaccine
GB8906897D0 (en) Dismantable trestle

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/49

A4 Supplementary search report drawn up and despatched

Effective date: 19960115

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960325